Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CPA2 | P48052 | 1/20 | 0.32 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25651348 | 0.91 | GLP1R (0.43) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL25651306 | 0.90 | GLP1R (0.44) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL25651291 | 0.87 | GLP1R (0.43) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL12122205 | 0.87 | GLP1R (0.45) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL12122206 | 0.87 | GLP1R (0.45) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL25651303 | 0.87 | GLP1R (0.43) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL20235709 | 0.84 | KDM4E (0.47) | FOLH1MEN1KMT2AKDM4EMAPK1 | |
| SCHEMBL24494718 | 0.80 | GLP1R (0.68) | GLP1RFOLH1 | |
| SCHEMBL25651302 | 0.80 | GLP1R (0.45) | GLP1RFOLH1MEN1KMT2AFAAH | |
| SCHEMBL12118613 | 0.79 | GLP1R (0.42) | GLP1RFOLH1MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190879-A1 | DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190879-A1 | DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885FOLH1 692/4885MEN1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.